Skip to content

Therapeutic Drug Monitoring of Triazoles for Individualized Precision Dosing

Therapeutic Drug Monitoring of Triazoles for Individualized Precision Dosing

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128363
Enrollment
Unknown
Registered
2026-07-18
Start date
2026-03-20
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fungal diseases

Interventions

Observation group:None

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Chinese patients receiving triazoles (fluconazole, voriconazole, itraconazole, posaconazole, and isavuconazole) at least once for antifungal therapy.

Exclusion criteria

Exclusion criteria: 1.Patients with unavailable or incomplete prescription and administration records (including time of dosing and administration) of triazole treatments.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with triazoles receiving TDM and target attainments for trough concentrations;

Secondary

MeasureTime frame
Proportion of patients with trough concentrations exceeding target range;Time from first dose to first TDM;Number of TDM for target attainment of trough concentrations;Time to target attainment of trough concentrations;Proportion of patients with at least one adjustment (e.g. dose, frequency) after first TDM;Target attainment with at least one adjustment after first TDM;All-cause inpatient mortality;Incidence of AESI;Overall response;Proportion of patients with AESI leading to treatment discontinuation;Clinical response;

Countries

China

Contacts

Public ContactZhang Jing

Huashan Hospital, Fudan University

13816357098@163.com+86 21 52888190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026